|
TyG index as a nominal variablea
|
TyG index as a continuous variableb
|
---|
HR
|
95% CI
|
P value
|
HR
|
95% CI
|
P value
|
---|
Crude model
|
4.610
|
3.253–6.533
|
< 0.001
|
3.367
|
2.677–4.235
|
< 0.001
|
Model 1
|
4.858
|
3.367–7.011
|
< 0.001
|
3.459
|
2.731–4.381
|
< 0.001
|
Model 2
|
3.774
|
2.553–5.580
|
< 0.001
|
2.900
|
2.194–3.832
|
< 0.001
|
Model 3
|
3.994
|
2.699–5.991
|
< 0.001
|
3.031
|
2.294–4.005
|
< 0.001
|
Model 4
|
4.062
|
2.732–6.040
|
< 0.001
|
3.208
|
2.400–4.289
|
< 0.001
|
- Model 1: adjusted for age, sex (female), BMI, SBP, DBP, smoking, drinking, duration of diabetes, dyslipidemia, prior MI, PCI, stroke and PVD
- Model 2: adjusted for variables included in Model 1 and diagnosis (NSTEMI), TC, HDL-C, eGFR, HbA1c, LVEF
- Model 3: adjusted for variables included in Model 2 and SYNTAX score, LM treatment, DCB use, complete revascularization and number of stents
- Model 4: adjusted for variables included in Model 3 and DAPT at discharge, DAPT interruption in 12 months, statins at discharge, statins interruption in 12 months, oral hypoglycemic agents (metformin, alpha-glucosidase inhibitor, sulfonylurea, dipeptidyl peptidase 4 inhibitor) at discharge and insulin at discharge
- Italic values indicate statistically significant associations
- TyG triglyceride glucose, HR hazard ratio, CI confidence interval
- aThe HR was examined regarding lower TyG index as reference (stratified by the optimal cutoff point of TyG index determined by ROC curve analysis)
- bThe HR was examined by per 1-unit increase of TyG index